Immune profiling and biomarker platforms to support pre-clinical research

WuXi Biology provides discovery and clinical biomarker services for immuno-oncology research. our technology platform includes a CAP-certified pathology lab, a flow cytometry and molecular biology lab, GCP compliance. Our Team is composed of well-trained immunologists, board-certified pathologists, biomarker experts and qualified technicians.

Flow Cytometry

  • >20 channel flow cytometry analysis,
  • Cover >60 cell marker/biomarker,
  • Baseline TIL (tumor-infiltrating leukocytes) data from >30 models,
  • Service covered TIL analysis,
  • Checkpoint/co-stimulatory marker analysis,
  • in vitro/in vivo phospho-flow,
  • Function analysis of immune cells,
  • High dimensional data mining

Pathology/multiplex IF

  • FFPE preparation/IHC/IF to support pre-clinical pathology diagnosis for drug safety evaluation, efficacy evaluation, etc.
  • Multiplex IF focusing on immune microenvironment analysis, including
    • immune cell infiltration analysis,
    • spatial-proximity analysis,
    • secretory protein source determination,
    • complex tissue structure determination,
    • evaluation of gene expression regulation
  • Provide biomarker testing in clinical studies, including
    • H&E and histology analysis,
    • FFPE sample process and slide cutting,
    • IHC/ICC,IF, EHC, TCT, FISH, DISH, RNAscope, multiplex-IF, etc.

Case study: Optimization of human tumor dissociation process to eliminate hTIM-3 and hLAG-3 degradations

NanoString-based gene expression profiling

  • Gene expression profiling with up to 800 genes in one panel,
  • Enabling GEP in difficult samples like FFPE,
  • Panel covering hot genes/pathways/function in immunology/oncology.

Single-cell RNA sequencing platform and bioinformatics services

One-stop service covering sample processing, library preparation, sequencing and bioinformatics analysis. Enabling cell type identification and phenotyping, differential gene expression analysis, functional enrichment and cell-cell interaction.

Molecular platform

  • Quantitative polymerase chain reaction (qPCR) to support efficacy and safety evaluation (e.g. target gene copy number variation in CAR-T cells, and replication competent lentivirus (RCL) level in CAR-T cell).
  • cMET exon14 skipping and EGFR mutation testing.